Nasdaq grants Daré extension until Aug 12, 2025 to regain listing compliance

Dare Bioscience, Inc.

Extension conditional on meeting stockholders' equity >$2.5M by April 30, 2025 and further increase by July 15, 2025.
Company must publicly disclose equity-raising transactions and provide 12-month projections by August 12, 2025.
Non-compliance with Nasdaq Rule 5550(b) since August 2024; risk of delisting if conditions not met.
Panel may reconsider extension or delist after April 30 if plan execution falters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.